Company: PETVW
Filing Date: 2025-11-14
Form Type: 10-Q
Source: 0001493152-25-023398
Chunk: 40

Company: PetVivo Holdings, Inc.
Filing Date: 2025-11-14
Form: 10-Q
Item: Part I, Item 1
Chunk 40
---
 Spryng® with OsteoCushion® technology addresses the affliction, loss of synovial fluid, and/or the
deterioration of joint cartilage, rather than treating just the symptoms and, to the best of our knowledge, has elicited minimal adverse
side effects in dogs and horses. Spryng®-treated dogs and horses have shown an increase in activity even after they no longer are
receiving pain medication or other treatments. Other treatments for osteoarthritis include steroid and/or hyaluronic acid injections,
which are used for treating pain, inflammation and/or joint lubrication, but can be slow acting and/or short lasting.

 25 

We
believe Spryng® is an optimal solution to safely improve joint function in animals for several reasons:

    ●
    Spryng® addresses the
    underlying problems which relate to deterioration of cartilage causing bones to contact each other and a lack of synovial fluid.
    Spryng® provides a biocompatible lubricious cushion to the joint, which establishes a barrier between the bones, thereby protecting
    the remaining cartilage and bone.

    ●
    Spryng® is easily administered
    with the standard intra-articular injection technique. Multiple joints can be treated simultaneously.

    ●
    Case studies indicate many
    dogs and horses have long-lasting multi-month improvement in lameness after having been treated with Spryng®.

    ●
    After receiving a Spryng®
    injection, many canines are able to discontinue the use of NSAID’s, eliminating the risk of negative side effects.

    ●
    Spryng® is an effective
    and economical solution for treating osteoarthritis. A single injection of Spryng® is approximately $600 to $900 per joint and
    typically lasts for at least 12 months.

Historically,
drug sales represent up to 30% of revenues at a typical veterinary practice (Veterinary Practice News). Revenues and margins at veterinary
practices are being eroded because online, big-box, and traditional pharmacies have recently started filling veterinary prescriptions.
Veterinary practices are looking for ways to replace lost prescription revenues with safe and effective products. Spryng® is a veterinarian-administered
medical device that should expand practice revenues and margins. We believe that the increased revenues and margins provided by Spryng®
will accelerate its adoption rate and propel it forward as the standard of care for canine